Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brent K Hollenbeck

Showing results (1-10 of 347) with videos related to

Pageof 35
Sort By:
Urologic Oncology|December 3, 2014
Commentary on "factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE)." Resnick MJ, Guzzo TJ, Cowan JE, Knight SJ, Carroll PR, Penson DF, VA Tennessee Valley Geriatric Research, Education and Clinical Care, Nashville, TN.: BJU Int 2013;111(2):213-20. [Epub 2012 Aug 29]. doi: 10.1111/j.1464-410X.2012.11423.xBrent K Hollenbeck
Urology|May 2, 2012
Editorial commentBrent K Hollenbeck
European Urology|October 12, 2013
Words of wisdom. Re: African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?Brent K Hollenbeck
Urologic Oncology|December 3, 2014
Commentary on "the burden of depression in prostate cancer." Jayadevappa R, Malkowicz SB, Chhatre S, Johnson JC, Gallo JJ, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.: Psychooncology 2012;21(12):1338-45. [Epub 2011 Aug 12]. doi: 10.1002/pon.2032Brent K Hollenbeck
Urologic Oncology|April 29, 2014
Commentary on "Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics." Chow WH, Shuch B, Linehan WM, Devesa SS, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.: Cancer 2013; 119(2):388-94. [Epub 2012 Nov 12]. doi: 10.1002/cncr.27690Brent K Hollenbeck
Urology|January 28, 2015
Editorial commentBrent K Hollenbeck
Urologic Oncology|December 3, 2014
Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University of Michigan, Ann Arbor, MI.: J Urol 2012;188(6):2114-9. [Epub 2012 Oct 18]. doi: 10.1016/j.juro.2012.08.005Brent K Hollenbeck
JAMA Network Open|October 4, 2022
Analyzing Trends in Urethral Suspension Procedures After Changes in Medicare Payment PolicyAvinash Maganty, Brent K Hollenbeck
Urologic Oncology|May 12, 2023
New technology in prostate cancer and financial toxicityAvinash Maganty, Brent K Hollenbeck
JAMA Network Open|September 16, 2024
Three-Dimensional Models in Surgery-A Procedural Aid or a Decisional Aid?Arnav Srivastava, Brent K Hollenbeck
Pageof 35

Showing results (1-10 of 347) with videos related to

Sort By:
Pageof 35
Urologic Oncology|December 3, 2014
Commentary on "factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE)." Resnick MJ, Guzzo TJ, Cowan JE, Knight SJ, Carroll PR, Penson DF, VA Tennessee Valley Geriatric Research, Education and Clinical Care, Nashville, TN.: BJU Int 2013;111(2):213-20. [Epub 2012 Aug 29]. doi: 10.1111/j.1464-410X.2012.11423.xBrent K Hollenbeck
Urology|May 2, 2012
Editorial commentBrent K Hollenbeck
European Urology|October 12, 2013
Words of wisdom. Re: African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?Brent K Hollenbeck
Urologic Oncology|December 3, 2014
Commentary on "the burden of depression in prostate cancer." Jayadevappa R, Malkowicz SB, Chhatre S, Johnson JC, Gallo JJ, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.: Psychooncology 2012;21(12):1338-45. [Epub 2011 Aug 12]. doi: 10.1002/pon.2032Brent K Hollenbeck
Urologic Oncology|April 29, 2014
Commentary on "Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics." Chow WH, Shuch B, Linehan WM, Devesa SS, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.: Cancer 2013; 119(2):388-94. [Epub 2012 Nov 12]. doi: 10.1002/cncr.27690Brent K Hollenbeck
Urology|January 28, 2015
Editorial commentBrent K Hollenbeck
Urologic Oncology|December 3, 2014
Commentary on "economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases." Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O׳Day K, Bramley T, Department of Urology, University of Michigan, Ann Arbor, MI.: J Urol 2012;188(6):2114-9. [Epub 2012 Oct 18]. doi: 10.1016/j.juro.2012.08.005Brent K Hollenbeck
JAMA Network Open|October 4, 2022
Analyzing Trends in Urethral Suspension Procedures After Changes in Medicare Payment PolicyAvinash Maganty, Brent K Hollenbeck
Urologic Oncology|May 12, 2023
New technology in prostate cancer and financial toxicityAvinash Maganty, Brent K Hollenbeck
JAMA Network Open|September 16, 2024
Three-Dimensional Models in Surgery-A Procedural Aid or a Decisional Aid?Arnav Srivastava, Brent K Hollenbeck
Pageof 35